BridgeBio Oncology Therapeutics, Inc.
BBOT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001869105
No open-market purchases or sales by BridgeBio Oncology Therapeutics, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $450.6M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in BridgeBio Oncology Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 34
- +3 vs. Q1 2025
- Shares held
- 16.7M
- +229.0K (+1.4%) vs. Q1 2025
- Total value
- $177.6M
- −$8.71M (−4.7%) vs. Q1 2025
- New holders
- 7
- 7 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BBOT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 65 | $450.6M |
| Q1 2026 | 67 | $513.8M |
| Q4 2025 | 52 | $724.7M |
| Q3 2025 | 42 | $657.5M |
| Q2 2025 | 34 | $177.6M |
| Q1 2025 | 31 | $186.3M |
| Q4 2024 | 32 | $172.7M |
| Q3 2024 | 31 | $171.1M |
| Q2 2024 | 31 | $167.4M |
| Q1 2024 | 29 | $166.9M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding BridgeBio Oncology Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,909,000 | $30.9M | 2.30% | 00.0% | Unchanged |
| BlackRock, Inc. | 1,498,865 | $15.9M | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,427,201 | $15.2M | 0.01% | +15,241+1.1% | Added |
| Adage Capital Partners GP, L.L.C. | 1,400,000 | $14.9M | 0.03% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 1,071,550 | $11.4M | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 897,251 | $9.53M | 0.01% | −199,131−18.2% | Reduced |
| Sculptor Capital LP | 800,000 | $8.50M | 0.14% | 00.0% | Unchanged |
| Silverarc Capital Management, LLC | 613,393 | $6.51M | 1.33% | 00.0% | Unchanged |
| Farallon Capital Management, L.L.C. | 600,000 | $6.39M | 0.03% | 00.0% | Unchanged |
| Harraden Circle Investments, LLC | 569,831 | $6.05M | 1.57% | +43,296+8.2% | Added |
| Berkley W R Corp | 445,195 | $4.73M | 0.29% | +445,195 | New |
| Toronto Dominion Bank | 444,377 | $4.72M | 0.01% | +306,377+222.0% | Added |
| ADAR1 Capital Management, LLC | 442,615 | $4.70M | 0.76% | −27,114−5.8% | Reduced |
| Perceptive Advisors LLC | 398,000 | $4.23M | 0.16% | 00.0% | Unchanged |
| Decagon Asset Management LLP | 348,223 | $3.70M | 2.89% | +108,820+45.5% | Added |
| StemPoint Capital LP | 315,812 | $3.29M | 1.06% | +114,912+57.2% | Added |
| Laurion Capital Management LP | 300,000 | $3.19M | 0.37% | 00.0% | Unchanged |
| Shaolin Capital Management LLC | 292,338 | $3.10M | 0.14% | +292,338 | New |
| Octagon Capital Advisors LP | 250,000 | $2.66M | 0.58% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 210,125 | $2.24M | 0.00% | +57,909+38.0% | Added |
| Clear Street LLC | 205,666 | $2.18M | 0.01% | +205,666 | New |
| Creative Planning | 200,000 | $2.12M | 0.00% | +200,000 | New |
| Acuta Capital Partners, LLC | 187,257 | $1.99M | 2.78% | 00.0% | Unchanged |
| Wellington Management Group LLP | 184,590 | $1.97M | 0.00% | 00.0% | Unchanged |
| TD Asset Management Inc | 144,772 | $1.54M | 0.00% | 00.0% | Unchanged |
| Hudson Bay Capital Management LP | 108,300 | $1.15M | 0.01% | +108,300 | New |
| Woodline Partners LP | 103,247 | $1.10M | 0.01% | 00.0% | Unchanged |
| Moore Capital Management, LP | 100,000 | $1.06M | 0.02% | 00.0% | Unchanged |
| K2 Principal Fund, L.P. | 100,000 | $1.06M | 0.19% | 00.0% | Unchanged |
| UBS Group AG | 68,534 | $727.8K | 0.00% | −24,126−26.0% | Reduced |
| Great Point Partners LLC | 29,381 | $312.0K | 0.20% | −344,452−92.1% | Reduced |
| FNY Investment Advisers, LLC | 27,184 | $289.0K | 0.12% | +27,184 | New |
| Geode Capital Management, LLC | 13,328 | $141.9K | 0.00% | +54+0.4% | Added |
| Fifth Lane Capital, LP | 10,500 | $111.8K | 0.14% | +10,500 | New |
| T. Rowe Price Investment Management, Inc. | 0 | $0 | 0.00% | −397,962−100.0% | Sold out |
| Fort Baker Capital Management LP | 0 | $0 | 0.00% | −374,683−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −189,285−100.0% | Sold out |
| Soros Fund Management LLCSuperinvestorSoros Fund Management | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |